New Market Report: Pharmaceutical Key Trends 2011

July 2, 2011 - PRLog -- The combined generics market size is valued at approximately $77bn in the US, Japan, the five major EU markets (France, Germany, Italy, Spain, and the UK), the BRIC markets (Brazil, Russia, India, and China), and Australia combined. With branded pharma set to lose approximately $100bn in sales due to the patent cliff, this presents a significant opportunity for generics players during 2011-15.

Features and benefits

* An overview generic uptake and market sizing
* Insight into the key drivers and resistors to generic uptake in key the developed and emerging markets.
* An examination of the major generics players and the strategies they have implemented in both the developed and emerging markets.
* Insight into future opportunities for generics players

------------------------------------------------------------
Full Report Details at
- http://www.fastmr.com/prod/158770_pharmaceutical_key_trends_2011_generics_market_overview_patent_cliff_set_to_drive_global_generic.aspx
------------------------------------------------------------

Highlights

In response to rising healthcare expenditure, governments in developed markets are looking bolster generic uptake in order to contain costs. Physician prescribing by international non-proprietary name (INN), in addition to automatic substitution and pharmacist incentives, are key tools to drive generic uptake.
In the US, despite the addition of many new customers and the continued drive to increase generic uptake as a result of the healthcare reform law, generics companies are set to experience further downward pricing pressures and will be forced to operate with ever-decreasing margins, focusing on consolidation and cost-cutting.
The BRIC countries represent a key growth market for the generics industry. Uptake of generics in these markets will be driven by continued population expansion, increased prosperity, and expanding healthcare coverage.

Your key questions answered

* Evaluate the drivers and resistors to generic uptake in the US, EU, Japan and BRIC markets
* Gain insight into the deal types between companies to bolster their position in generics markets
* Identify which key small molecules are facing patent expiry and provide opportunities for generic producers


Report Table of Contents:

Executive Summary
Introduction
Strategic scoping and focus
Key findings
Key growth drivers and resistors facing healthcare payers and pharma
Generics Market Dynamics
Drivers and Resistors to Generic Uptake
Key global gener

About Datamonitor

The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment.  View more research from Datamonitor at http://www.fastmr.com/catalog/publishers.aspx?pubid=1002

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

# # #

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.